Market closedNon-fractional
Aura Biosciences/AURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Aura Biosciences
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Ticker
AURA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
89
Website
www.aurabiosciences.com
Aura Biosciences Metrics
BasicAdvanced
$509M
Market cap
-
P/E ratio
-$1.85
EPS
0.37
Beta
-
Dividend rate
Price and volume
Market cap
$509M
Beta
0.37
Financial strength
Current ratio
21.965
Quick ratio
20.995
Long term debt to equity
7.941
Total debt to equity
9.254
Management effectiveness
Return on assets (TTM)
-24.90%
Return on equity (TTM)
-40.43%
Valuation
Price to book
2.41
Price to tangible book (TTM)
2.41
Price to free cash flow (TTM)
-6.019
Growth
Earnings per share change (TTM)
-6.44%
3-year earnings per share growth (CAGR)
-71.03%
What the Analysts think about Aura Biosciences
Analyst Ratings
Majority rating from 6 analysts.
Aura Biosciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$20M
-10.86%
Profit margin
0.00%
NaN%
Aura Biosciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.48
-$0.48
-$0.56
-$0.40
-
Expected
-$0.49
-$0.52
-$0.41
-$0.49
-$0.45
Surprise
-1.96%
-7.83%
35.86%
-17.73%
-
Aura Biosciences News
AllArticlesVideos
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024
GlobeNewsWire·2 months ago
Aura Biosciences to Participate in Upcoming Investor Conferences
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aura Biosciences stock?
Aura Biosciences (AURA) has a market cap of $509M as of July 27, 2024.
What is the P/E ratio for Aura Biosciences stock?
The price to earnings (P/E) ratio for Aura Biosciences (AURA) stock is 0 as of July 27, 2024.
Does Aura Biosciences stock pay dividends?
No, Aura Biosciences (AURA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Aura Biosciences dividend payment date?
Aura Biosciences (AURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Aura Biosciences?
Aura Biosciences (AURA) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Aura Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.